Rocket Pharmaceuticals RCKT
NASDAQ RCKT
$2.56 -0.03 (-1.16%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rocket Pharmaceuticals (RCKT) Non Operating Interest Expenses (2014 - 2026)

Updated

Rocket Pharmaceuticals' Non Operating Interest Expenses was $473,000 in Q2 2026, unchanged from $473,000 a year earlier and unchanged from the prior quarter.

Analysis

Rocket Pharmaceuticals (RCKT) Non Operating Interest Expenses (2014 - 2026) Analysis & Trends

On a trailing twelve-month basis, Rocket Pharmaceuticals' Non Operating Interest Expenses was $1.89 million through Jun 30, 2026, up 0.2% year-over-year; for FY2025, it was $1.89 million, up 0.3% from FY2024.

  • Non Operating Interest Expenses has now increased for three consecutive years, though with a five-year compound annual growth rate of -23.0% (FY2020 to FY2025).
  • In earlier years, Non Operating Interest Expenses was $1.89 million in FY2024 (+0.6%), $1.88 million in FY2023 (+0.7%), $1.86 million in FY2022 (-37.5%) and $2.98 million in FY2021 (-57.3%).
  • Quarterly Non Operating Interest Expenses has moved between $463,000 (Q4 2021) and $534,000 (Q3 2021) over five years.
  • Compared with a year earlier, Non Operating Interest Expenses was higher in six of the last eight quarters, with growth averaging 0.3%.
  • The best year-over-year quarter for Non Operating Interest Expenses over five years was Q2 2022 (growth of 85.3%); the worst was Q1 2022 (a decline of 73.2%).
  • Per Business Quant data, RCKT's Non Operating Interest Expenses in the three quarters before Q2 2026 was $473,000 (Q1 2026), $473,000 (Q4 2025) and $473,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn -
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 281.00 Mn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -462.00 Mn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -435.00 Mn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 673.00 Mn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 247.00 Mn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -
10 Rocket Pharmaceuticals 283.71 Mn 283.71 Mn - 473,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 473,000.00
Mar 31, 2026 473,000.00
Dec 31, 2025 473,000.00
Sep 30, 2025 473,000.00
Jun 30, 2025 473,000.00
Mar 31, 2025 472,000.00
Dec 31, 2024 473,000.00
Sep 30, 2024 471,000.00
Jun 30, 2024 471,000.00
Mar 31, 2024 471,000.00
Dec 31, 2023 470,000.00
Sep 30, 2023 469,000.00
Jun 30, 2023 468,000.00
Mar 31, 2023 468,000.00
Dec 31, 2022 467,000.00
Sep 30, 2022 465,000.00
Jun 30, 2022 465,000.00
Mar 31, 2022 464,000.00
Dec 31, 2021 463,000.00
Sep 30, 2021 534,000.00
API Access

Rocket Pharmaceuticals Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=RCKT&period=max&api_key=YOUR_API_KEY